Breakthrough Lymphoma Treatment Achieves Remarkable 87% Response Rate in Advanced DLBCL Patients

Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant

Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell transplant or CAR T-cell therapy.

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Jun 15, 2025-

Epcoritamab/R-ICE Shows High Response in R/R DLBCL, Aids ASCT Eligibility

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Breakthrough Lymphoma Treatment Achieves Remarkable 87% Response Rate in Advanced DLBCL Patients

New epcoritamab combination therapy demonstrates powerful efficacy for resistant lymphoma, with 65% complete response rate. See detailed trial outcomes and safety data.